Warning letter
Compounded Solutions in Pharmacy: warning letter of Sep 18, 2017
FDA warning letter 532962 · New England District Office
Key facts
| Reference number | 532962 |
|---|---|
| Company | Compounded Solutions in Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Sep 18, 2017 |
| Posted date | Sep 18, 2017 |
| Issuing office | New England District Office |
| Product type | Drugs |
| CFR sections cited | 200.10(b), 211.42(c)(10)(i), 211.42(c)(10)(iv), 211.67(a), 211.113(b), 210.1(b) |
| Inspection city | Monroe |
| Inspection ZIP | 06468 |
| Inspection start date | Feb 22, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: